A prospective combination of phase II and phase III in drug development

DOI10.1007/BF03263544zbMATH Open1301.62107OpenAlexW2070405587MaRDI QIDQ478229FDOQ478229

Authors: Antonella Bacchieri, Adelchi Azzalini 

Publication date: 3 December 2014

Published in: Metron (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1007/bf03263544

Recommendations

• Theory of drug development
• Phase 2 and 3 Combination Designs to Accelerate Drug Development
• A Parallel Phase I/II Clinical Trial Design for Combination Therapies
• Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts
• A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations

zbMATH Keywords

skew-normal distributionlikelihood-based inferenceadaptive designsconditional powerdrug development

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Cites Work

• Graphical models for skew‐normal variates
• On the Unification of Families of Skew-normal Distributions
• Definition and probabilistic properties of skew-distributions.
• Evaluation of Experiments with Adaptive Interim Analyses
• Phase 2 and 3 Combination Designs to Accelerate Drug Development

Cited In (9)

• Expressions for moments of order statistics and records from the skew-normal distribution in terms of multivariate normal orthant probabilities
• Statistical methodology for screening studies with qualitative/quantitative mixtures
• Some properties of the unified skew-normal distribution
• Phase 2 and 3 Combination Designs to Accelerate Drug Development
• A closed-form filter for binary time series
• Records for time-dependent stationary Gaussian sequences
• Title not available (Why is that?)
• Bayesian Conjugacy in Probit, Tobit, Multinomial Probit and Extensions: A Review and New Results
• Interphase Clinical Trials: Phase III/Phase IV

Uses Software

• R

This page was built for publication: A prospective combination of phase II and phase III in drug development

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q478229)